aTyr Pharma | LIFE - Selling And Administration Expenses


aTyr Pharma reported $700.63K in Selling and Administration Expenses for its fiscal quarter ending in March of 2026.





Selling And Administration Expenses Change Date
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Ardelyx USD 102.27M 26.35M Mar/2026
aTyr Pharma USD 700.63K 81.56M Mar/2026
Biogen USD 554.3M 128.2M Mar/2026
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.43M 222K Mar/2026
CSL USD 1.23B 498M Dec/2025
Curis USD 1.34M 3.45M Dec/2025
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Grifols EUR 320.45M 12.65M Dec/2025
Lakefront Biotherapeutics EUR 35.5M 8.91M Mar/2026
Novartis USD 3.14B 296M Mar/2026
Roche Holding CHF 7.28B 3.99B Dec/2025
United Therapeutics USD 156.6M 34M Mar/2026
Xoma USD 11M 2.54M Jun/2024